Welcome to our dedicated page for Tactile Systems news (Ticker: TCMD), a resource for investors and traders seeking the latest updates and insights on Tactile Systems stock.
Tactile Systems Technology, Inc. reports news as a medical technology company that develops and markets at-home therapies for chronic disorders. Its updates center on lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease, including products and platforms such as Flexitouch Plus, AffloVest airway clearance devices and LymphaTech's digital 3D measurement and monitoring technology.
Recurring company developments include quarterly financial results, clinical evidence for home-based therapies, FDA device clearances, product portfolio expansion, order-management and reimbursement workflow initiatives, acquisitions, share repurchase activity and board governance changes. The company's news also describes its work with clinicians to expand awareness and access to care for patients using at-home therapy systems.
Tactile Systems Technology (Nasdaq: TCMD) reported second quarter 2026 revenue of $85.7 million, up 9% year-over-year, driven by a 12% increase in lymphedema product sales and rentals, partially offset by a 7% decline in airway clearance revenue tied to AffloVest launch-related inventory dynamics.
Gross margin rose to 76% from 75%, and net income more than doubled to $7.8 million ($0.34 per diluted share). Adjusted EBITDA increased to $11.4 million from $7.7 million. For the first six months, revenue grew 15% to $161.0 million and adjusted EBITDA reached $15.1 million. The company ended June 30, 2026 with $69.9 million in cash and no debt, repurchasing $5.3 million of stock in Q2.
Tactile Systems updated 2026 revenue guidance to $360–$366 million (9–11% growth), narrowing the prior $360–$368 million range, while maintaining adjusted EBITDA guidance of $49–$51 million. Strategic highlights included an exclusive U.S. distribution agreement for ElastiMed’s MyoSleeve device for VA and DoD patients, commercial launch of the next-generation AffloVest airway clearance system, and publication of six-month clinical results from a Flexitouch Plus trial in head and neck cancer-related lymphedema.
Tactile Medical (Nasdaq: TCMD) will release its second quarter fiscal 2026 financial results after the market close on Monday, August 10, 2026. Management will host a conference call and live webcast at 5:00 p.m. Eastern Time the same day to discuss quarterly results.
Tactile Medical (Nasdaq: TCMD) entered an exclusive U.S. distribution agreement with ElastiMed to supply the MyoSleeve™ wearable, non-pneumatic lower-leg compression device to Department of Veterans Affairs (VA) and Department of Defense (DoD) patients. The device has FDA 510(k) clearance for chronic edema, lymphedema, and venous insufficiency.
According to Tactile Medical, it paid $3 million upfront for exclusive VA/DoD distribution rights and agreed to minimum purchase and promotional obligations. The company plans to use its existing sales, billing, and patient-support infrastructure to commercialize MyoSleeve as an early-stage and complementary therapy option.
Tactile Medical (Nasdaq: TCMD) announced the full commercial launch of its next-generation AffloVest high-frequency chest wall oscillation therapy system. The device retains its indications for chronic neuromuscular and respiratory conditions, including cystic fibrosis and bronchiectasis, in pediatric through geriatric patients.
Enhancements include a lighter, more adjustable vest, an intuitive controller, and built-in Wi‑Fi and Bluetooth for connected care. These features are designed to improve comfort, simplify setup and operation, and provide real-world therapy data to patients, clinicians, and DME providers to support adherence and reimbursement.
Tactile Medical (Nasdaq: TCMD) announced that management will present at the William Blair 46th Annual Growth Stock Conference at the Loews Hotel in Chicago from June 2-4, 2026. The company’s presentation is scheduled for Tuesday, June 2, at 9:20 a.m. CT.
A live audio webcast and replay will be available in the “Events & Webcasts” section of Tactile Medical’s investor relations website. Tactile Medical develops at-home therapies for chronic conditions such as lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease.
Tactile Systems Technology (Nasdaq: TCMD) reported Q1 2026 results: revenue $75.3M (+23% YoY), gross margin 76.5%, net loss $1.8M (‑$0.08/share), and Adjusted EBITDA $3.7M. The company repurchased $1.1M of stock, closed the LymphaTech acquisition, received FDA 510(k) clearance for a next‑gen AffloVest device, and updated 2026 revenue guidance to $360M–$368M.
Balance sheet: cash $75.0M, no borrowings; $23.9M remains available under the $25M repurchase program.
Tactile Medical (Nasdaq: TCMD) will release first quarter fiscal 2026 results after market close on May 4, 2026. Management will host a conference call and webcast at 5:00 p.m. ET the same day; a replay will be available for two weeks and the webcast will be archived on the investor site.
Tactile Medical (Nasdaq: TCMD) appointed Andrea Pearson to its Board of Directors effective March 9, 2026, and named her to the Compliance & Reimbursement and Nominating & Corporate Governance Committees. Ms. Pearson brings 25+ years of healthcare growth, product and marketing experience.
Her background includes senior roles at DispatchHealth and HealthGrades, where she led large-scale market expansion and audience growth, and most recently served as Growth Advisor and CMO at Harbor Health. The appointment supports Tactile Medical's focus on expanding access and clinical engagement for at-home therapies.
Tactile Medical (Nasdaq: TCMD) reported Q4 2025 revenue of $103.6M (+21% YoY) and full-year 2025 revenue of $329.5M (+12% YoY). Gross margin expanded to 78% in Q4 and 76% for the year. Adjusted EBITDA rose to $22.9M in Q4 and $44.8M for 2025.
Key balance-sheet moves: repaid $26.3M term loan, repurchased $26.5M of stock, and ended 2025 with $83.4M cash. 2026 guidance: revenue $357M–$365M and adjusted EBITDA $49M–$51M.
Tactile Medical (Nasdaq: TCMD) acquired LymphaTech on February 17, 2026 for an upfront cash payment of $6.8 million, plus potential milestone-based additional consideration. The deal adds LymphaTech’s clinically validated 3D full-body measurement platform to Tactile’s lymphedema portfolio and brings founders into Tactile to drive commercialization and research.
The acquisition aims to improve disease identification, enable longitudinal monitoring, support compression garment digitization, and strengthen R&D for next‑generation lymphatic therapies.